Neurocrine Biosciences (NBIX) plans to present at the Jefferies Global Healthcare Conference in London on 17 November 2026, shortly after sharing new INGREZZA tardive dyskinesia quality of life and functionality data.
Neurocrine Biosciences shares trade at US$165.92, with a 30 day share price return of 21.13% and an 18.01% share price gain year to date. The 1 year total shareholder return of 20.18% and 5 year total shareholder return of 88.85% point to momentum that has been building over a multi year period as INGREZZA data and upcoming conference visibility keep the story in focus.
Scan beyond Neurocrine Biosciences and see how other neurology and healthcare specialists with strong fundamentals line up by running the curated list of solid balance sheet and fundamentals (24 results).
After a 21% move in 30 days and a track record of multi year gains, Neurocrine Biosciences still trades at a discount to both analyst targets and intrinsic estimates. Is the market sensibly cautious or too restrained on this one?
Neurocrine Biosciences closed at $165.92, while the analyst consensus Narrative on Simply Wall St marks fair value at $206.81 based on detailed revenue and earnings forecasts. That gap frames INGREZZA, CRENESSITY and the late stage CNS pipeline as the key swing factors for where the valuation settles.
The current valuation implies that Neurocrine Biosciences'' share price already reflects INGREZZA’s IRA related pricing drag and VYKAT XR concerns but still assigns meaningful upside if the company proves this multiproduct, late stage pipeline story is as undervalued as the narrative claims.
See why 52 investors see Neurocrine Biosciences as 20% undervalued.
Result: Fair Value of $206.81 (UNDERVALUED)
Still, INGREZZA pricing pressure from Medicare rules and lingering VYKAT XR safety and uptake questions could quickly challenge the upbeat Neurocrine Biosciences narrative that investors are leaning on.
Find out about the key risks to this Neurocrine Biosciences narrative.
Optimistic narrative or overconfident crowd, either way the quickest way to test the Neurocrine Biosciences story is to pull up the data and pressure test the assumptions that matter to you, then weigh those findings against the 4 key rewards.
If Neurocrine Biosciences has sharpened your focus, use that momentum to review fresh stock ideas before the next wave of opportunities passes you by.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com